Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)

  • Technology appraisal
  • TA774
  • Published: 

History

Documents created during the development process.

Notes

Final scope

Final matrix

NICE?s response to comments on the draft scope and provisional matrix

Equality impact assessment

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide: provisional scope

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide: provisional matrix

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide: draft scope for consultation (pre-referral) - November 2014

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide: provisional matrix (pre-referral) - November 2014